Rheumatoid Arthritis Completed Phase 3 Trials for Tofacitinib (DB08895)

Also known as: RA / Rheumatic Arthritis / Arthritis, Rheumatoid / Arthritis,Rheumatoid / Rheumatoid Arthritis (RA) / Rheumatoid Arthritis(RA) / Arthritis, Rheumatoid (RA) / Systemic rheumatoid arthritis / Arthritis rheumatoid / Rheumatoid arthritis, unspecified / R arthritis / Rh arthritis / Atrophic arthritis

IndicationStatusPhase
DBCOND0027961 (Rheumatoid Arthritis)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00960440Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) InhibitorsTreatment
NCT00413699Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid ArthritisTreatment
NCT01039688Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTXTreatment
NCT00814307A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid ArthritisTreatment
NCT00856544A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis MedicationsTreatment
NCT00847613A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background MethotrexateTreatment
NCT02566967An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural PerspectiveTreatment
NCT02281552A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid ArthritisTreatment
NCT00661661Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In JapanTreatment
NCT00853385A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid ArthritisTreatment